drugset / Trial / NCT06169319

A Study to Assess Collagenase Clostridium Histolyticum (CCH) in the Treatment of Plantar Fasciitis (PFA)

NCT06169319

Phase 2 Completed 231 enrolled Endo USA Inc., a Keenova Therapeutics Company
RandomizedParallel-groupDouble-blindTreatment

Summary

This study will assess the efficacy, safety, and tolerability of 2 different doses of collagenase clostridium histolyticum (CCH) (previously known as EN3835) compared to placebo.

Timeline

Start
2024-01-03
Primary completion
2024-09-30
Completion
2024-09-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Collagenase Clostridium Histolyticum Protein / enzyme biologic Other

Indications